TCA
ORGO icon

Transcend Capital Advisors’s Organogenesis Holdings ORGO Stock Holding History

Transcend Capital Advisors’s Portfolio ORGO Stock Details ORGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,000
Closed -$38.2K – 532
2023
Q3 		$38.2K Hold
12,000
– – ﹤0.01% 482
2023
Q2 		$39.8K Hold
12,000
– – ﹤0.01% 481
2023
Q1 		$25.6K Hold
12,000
– – ﹤0.01% 475
2022
Q4 		$32.3K Buy
+12,000
New +$35K ﹤0.01% 484

Other funds holding ORGO

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Transcend Capital Advisors's ORGO Position: Q4 2023 in Review

Transcend Capital Advisors sold out of Organogenesis Holdings (ORGO) in Q4 2023, closing a stake of 12,000 shares — an estimated $38.2K sold.

Transcend Capital Advisors first reported a position in ORGO in Q4 2022 and held it in 4 quarters. The position peaked at $39.8K in Q2 2023. 108 funds tracked by Wall St. Rank hold ORGO as of Q4 2023.

  • Transcend Capital Advisors reported no remaining Organogenesis Holdings position as of Q4 2023 after selling out during the quarter.
  • Transcend Capital Advisors sold 12,000 Organogenesis Holdings shares in Q4 2023, an estimated $38.2K.
  • Transcend Capital Advisors first reported a position in Organogenesis Holdings in Q4 2022 and held it in 4 quarters.
  • Transcend Capital Advisors's Organogenesis Holdings position peaked at $39.8K in Q2 2023.
  • 108 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q4 2023.

Based on Transcend Capital Advisors's 13F filing for Q4 2023, filed 5 Feb 2024.